Clinical Trials Logo
NCT number NCT03390933
Study type Interventional
Source MetroHealth Medical Center
Contact Noreen Roman
Phone 216-778-3130
Email nroman@metrohealth.org
Status Not yet recruiting
Phase Phase 4
Start date January 12, 2018
Completion date November 30, 2023

Clinical Trial Summary

Depression is present in about 20-30% of hemodialysis patients and is associated with morbidity and mortality. However, depression is inadequately diagnosed and treated among dialysis patients. This is due in part to the overlap between depressive symptoms (e.g. appetite change, trouble sleeping, feeling tired) and symptoms related to persistent metabolic derangements in hemodialysis patients (e.g. nausea, nocturnal cramps, feeling washed out after treatment). The overlap between depressive symptoms and dialysis-related complications makes it difficult to diagnose and therefore to treat depression. In addition, prescription of antidepressant medication may increase an already high pill burden and result in poor adherence. Moreover, the evidence base to guide depression treatment among hemodialysis patients is limited. In the investigators' previous work, they developed methods to use latent variables and structural equation modeling to isolate depressive symptoms. Other investigators have demonstrated that directly observed treatment enhances the effectiveness of tuberculosis and HIV treatment.

The investigators now propose a cross-sectional study followed by a randomized controlled trial at 17 dialysis facilities. The cross-sectional study will involve assessments of depressive symptoms (using the PHQ-9 screening instrument) as well as dialysis-related complications. They will then use structural equation modeling to develop and validate a hemodialysis-specific PHQ-9 (hdPHQ-9) that will isolate depressive symptoms. The trial will involve 216 patients with confirmed depression who will be randomly assigned to (a) directly observed weekly antidepressant treatment with fluoxetine or (b) referral to their nephrologists, their primary care physicians, or nearby mental health providers. The primary outcome of the trial will be remission of depression at 12 weeks. The trial results will also be used to compare the responsiveness of the PHQ-9 and the hdPHQ-9. The investigators anticipate that the hdPHQ-9 will be a valid and responsive instrument that will isolate depressive symptoms in hemodialysis patients and ultimately improve the screening and diagnosis of depression. The investigators also expect that directly observed weekly fluoxetine treatment will be an effective way to manage depression among hemodialysis patients.


Clinical Trial Description

Depression is present in about 20-30% of hemodialysis patients and is associated with morbidity and mortality. However, depression is inadequately diagnosed and treated among dialysis patients. This is due in part to the overlap between depressive symptoms (e.g. appetite change, trouble sleeping, feeling tired) and symptoms related to persistent metabolic derangements in hemodialysis patients (e.g. nausea, nocturnal cramps, feeling washed out after treatment). The overlap between depressive symptoms and dialysis complications makes it difficult to diagnose and therefore to treat depression. In addition, prescription of antidepressant medication may increase an already high pill burden and result in poor adherence. Moreover, the evidence base to guide depression treatment among hemodialysis patients is limited. In the investigators' previous work, they developed methods to use latent variables and structural equation modeling to isolate depressive symptoms. Other investigators have demonstrated that directly observed treatment enhances the effectiveness of tuberculosis and HIV treatment.

The investigators now propose a cross-sectional study followed by a randomized controlled trial at 17 dialysis facilities. The cross-sectional study will involve assessments of depressive symptoms (using the PHQ-9 screening instrument) as well as dialysis-related complications. They will then use structural equation modeling to develop and validate a hemodialysis-specific PHQ-9 (hdPHQ-9) that will isolate depressive symptoms. The trial will involve 216 patients with confirmed depression who will be randomly assigned to (a) directly observed weekly antidepressant treatment with fluoxetine or (b) referral to their nephrologists, their primary care physicians, or nearby mental health providers. The primary outcome of the trial will be remission of depression at 12 weeks. The trial results will also be used to compare the responsiveness of the PHQ-9 and the hdPHQ-9.

The investigators anticipate that the hdPHQ-9 will be a valid and responsive instrument that will isolate depressive symptoms from dialysis complications and ultimately improve the screening and diagnosis of depression. They also expect that directly observed weekly fluoxetine treatment will be an effective way to manage depression among hemodialysis patients.

Innovative features of the proposed project include the use of latent variables to address overlap, administration of a long acting weekly antidepressant, directly observed treatment, and a rigorous randomized controlled trial design. The project has the potential not only to improve the diagnosis and management of depression among hemodialysis patients but also to improve their morbidity and mortality. Furthermore, it may serve as a model for future studies to isolate symptoms among overlapping medical conditions.

Aim A. To develop and validate a self-reported depression screening instrument that isolates depressive symptoms from hemodialysis-related complications.

Hypothesis: A hemodialysis-specific PHQ-9 (hdPHQ-9) will isolate depressive symptoms from dialysis complications.

Aim B. To determine the impact of directly observed weekly fluoxetine treatment on remission of depression among hemodialysis patients.

Hypothesis: Patients randomized to directly observed fluoxetine treatment will have higher rates of depression remission compared to patients randomized to referral.

Aim C. To examine the responsiveness of the new depression screening instrument to depression treatment.

Hypothesis: Fluoxetine treatment will be associated with larger improvements in hdPHQ-9 scores than in PHQ-9 scores.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care Phase 2/Phase 3
Recruiting NCT03167372 - Pilot N-of-1 Light Therapy Study N/A
Enrolling by invitation NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Enrolling by invitation NCT03272555 - WILD 5 Wellness: A 30-Day Intervention N/A
Not yet recruiting NCT03234439 - Digital Tools for Coping With Chronic Pain N/A
Recruiting NCT02543983 - Neurobiology of Suicide Phase 2
Recruiting NCT03129204 - Sensation Awareness Focused Training for Spouses N/A
Completed NCT01198197 - PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A Early Phase 1
Recruiting NCT00024635 - Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers N/A
Not yet recruiting NCT03293797 - Ultra-Brief Intervention to Reduce Depressive and Anxious Symptoms N/A
Not yet recruiting NCT03254719 - Care Outcomes for Chiropractic Outpatient Veterans N/A
Not yet recruiting NCT03196544 - Novel Behavioral Intervention to Enhance Social Connections in Anxiety and Depression N/A
Recruiting NCT02924090 - Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Phase 4
Recruiting NCT02777112 - The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression in Canadian Working Men N/A
Recruiting NCT02902159 - RCT of the Effectiveness of Big White Wall Compared to Other Online Support N/A
Recruiting NCT02919280 - Dallas 2K: A Natural History Study of Depression N/A
Recruiting NCT02939560 - TMS for Adults With Autism and Depression N/A
Recruiting NCT02970825 - Move and Feel Good : Effects of Intensive Physical Training on Brain Plasticity, Cognition and Psychological Well-being. N/A
Recruiting NCT02920840 - Brain-oscillation Synchronised Stimulation of the Prefrontal Cortex N/A